Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance
NCT ID: NCT02475421
Last Updated: 2018-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2015-05-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes
NCT00704795
Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes
NCT02232971
Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia
NCT02337660
Hepatic Metabolic Changes in Response to Glucagon Infusion
NCT03526445
Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion
NCT02010827
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy, lean subjects
Healthy subjects with BMI \< 27 kg/m\^2
Glucagon
One hour glucagon-clamp followed by one hour of blood sampling
Healthy, obese subjects
Healthy subjects with BMI \> 33 kg/m\^2
Glucagon
One hour glucagon-clamp followed by one hour of blood sampling
Diabetic, lean subjects
Diabetic subjects with BMI \< 27 kg/m\^2
Glucagon
One hour glucagon-clamp followed by one hour of blood sampling
Diabetic, obese subjects
Diabetic subjects with BMI \> 33 kg/m\^2
Glucagon
One hour glucagon-clamp followed by one hour of blood sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glucagon
One hour glucagon-clamp followed by one hour of blood sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Caucasians above 35 years of age with diet or/and metformin-treated type 2 diabetes of at least 3 month duration (diagnosed according to World Health Organization (WHO) criteria
* BMI either below 27 or above 33 kg/m\^2
* Normal haemoglobin
* Informed consent
Subjects with NGT
* Caucasians above 35 years of age
* BMI either below 27 or above 33 kg/m\^2
* Normal HbA1c (according to WHO criteria)
* Normal haemoglobin
* Informed consent
Exclusion Criteria
* Inflammatory bowel disease
* Operation within the last 3 months
* Severe kidney disease (eGFR \< 60 ml/min)
* Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) \>2×normal values)
* Pregnancy and/or breastfeeding
* Age above 80 years
* Any condition that the investigators feel would interfere with trial participation
Subjects with NGT
* Diabetes
* Prediabetes (impaired FPG or HbA1c above 42 mmol/mol)
* First-degree relatives with diabetes
* Inflammatory bowel disease
* Intestinal resection
* Severe kidney disease (eGFR \< 60 ml/min)
* Liver disease (ALA T and/or serum ASA T \>2×normal values)
* Pregnancy and/or breastfeeding
* Age above 80 years Any condition that the investigators feel would interfere with trial participation
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
European Foundation for the Study of Diabetes
OTHER
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asger Lund
Asger Lund, MD, PhD-student, University Hospital, Gentofte, Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Diabetes Research, Department of Medicine, Gentofte Hospital
Hellerup, Copenhagen, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-1-2014-066
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.